More info
Description
Composition Doxazosin (in the form of mesylate) 2 mg Pharmacological action Selective competitive blocker of postsynaptic .1-adrenoreceptors. It causes the expansion of peripheral vessels, which leads to a decrease in round focal disease and a decrease in blood pressure. Helps increase HDL / total cholesterol, lower total triglycerides and cholesterol. With prolonged use, there is regression of left ventricular hypertrophy, suppression of platelet aggregation and increase in the content of plasminogen activator in the tissues. The blockade of the .1-adrenoreceptors located in the stroma and the capsule of the prostate gland in the bladder neck leads to a decrease in resistance and pressure in the urethra, and a decrease in resistance in its internal opening. Improves urodynamics and reduces the manifestations of benign prostatic hyperplasia.
Dosage and administration
: Initial dose is 1 mg / day. After 1-2 weeks, depending on the clinical situation, the dose may be increased to 2 mg / day, and then after 1-2 weeks to 4 mg, 8 mg or 16 mg / day to achieve the optimal therapeutic effect. On average, the daily dose is 2-4 mg. Maximum dose: 16 mg / day. Precautions During the period of treatment may worsen psoriasis. With pheochromocytoma, propranolol can be used only after taking an alpha blocker. After a long course of treatment, propranolol should be discontinued gradually, under the supervision of a physician. Against the background of treatment with propranolol, IV administration of verapamil, diltiazem should be avoided. A few days before anesthesia, you must stop taking propranolol or pick up a remedy for anesthesia with minimal negative inotropic effects. Influence on the ability to drive vehicles and control mechanisms In patients whose activities require increased attention, the question of the use of propranolol on an outpatient basis should be addressed only after evaluating the individual response of the patient. Side effect From the side of the cardiovascular system: orthostatic reactions (including fainting), tachycardia, arrhythmia, peripheral edema. On the part of the digestive system: nausea. From the side of the central nervous system: dizziness, headache, fatigue, irritability, asthenia, drowsiness.Other: rhinitis. Cautions should be used with caution in pulmonary edema caused by mitral stenosis or aortic stenosis. heart failure with increased cardiac output. right ventricular failure due to embolism of the pulmonary artery or exudative pericarditis. left ventricular failure with low filling pressure. disorders of cerebral circulation. in elderly patients. simultaneous use with PDE-5 inhibitors (the threat of symptomatic arterial hypotension). with liver failure. during pregnancy. during surgery for cataract removal. After receiving doxazosin in the initial dose may develop orthostatic hypotension (the phenomenon of the first dose), especially in the standing position. Most often, this condition is observed in patients with hypovolemia, sodium deficiency, in the elderly. In this regard, the initial dose is recommended to take at bedtime. Clinical experience with doxazosin in children is absent. Influence on the ability to drive vehicles and control mechanisms In the period of receiving doxazosin, especially at the beginning of treatment, caution should be exercised when performing work that requires an increased rate of psychomotor reactions, due to the possible development of drowsiness, dizziness. Use during pregnancy and breastfeeding Adequate and strictly controlled studies of the safety of doxazosin during pregnancy and lactation (breastfeeding) have not been conducted. Application is possible only in cases where the potential benefit to the mother outweighs the potential risk to the fetus or child. Type: Drug Quantity in the package, pcs: 20 Shelf life: 24 months Active ingredient: Doxazosin (Doxazosin) Route of administration: Oral Vacation procedure: Prescription Release form: Prescription Storage conditions: In a dry place, In a dark place, Keep out of reach of children Maximum storage temperature, ° С: 25 Pharmacological group: C02CA04 Doxazosin Minimum age: 18 yearsActive ingredients
Doxazosin
Release form
Pills
Composition
Doxazosin (in the form of mesylate) 2 mg
Pharmacological effect
Selective competitive blocker postsynaptic & # 945 .1-adrenergic receptors.It causes the expansion of peripheral vessels, which leads to a decrease in round focal disease and a decrease in blood pressure. Helps increase HDL / total cholesterol, lower total triglycerides and cholesterol. With prolonged use, there is regression of left ventricular hypertrophy, suppression of platelet aggregation and increase in the content of plasminogen activator in the tissues. Blockade of & # 945 .1-adrenergic receptors located in the stroma and the capsule of the prostate gland in the bladder neck leads to a decrease in resistance and pressure in the urethra, a decrease in resistance in its internal opening. Improves urodynamics and reduces the manifestations of benign prostatic hyperplasia.
Indications
Arterial hypertension. Benign prostatic hyperplasia (symptomatic treatment).
Contraindications
Severe liver failure. urinary tract infections . anuria. progressive renal failure. arterial hypotension with orthostatic disorders (including history). hypotension (refers only to the indication of benign prostatic hyperplasia). concomitant obstruction of the upper urinary tract. chronic urinary tract infections. Bladder stones. obstructive disorders of the digestive tract. obstruction of the esophagus. reducing the diameter of the lumen of the digestive tract of any degree. lactose intolerance, lactase deficiency or glucose-galactose malabsorption (due to the presence of lactose in the composition). children and adolescents up to 18 years. lactation period (breastfeeding). hypersensitivity to quinazoline derivatives (for example, prazosin, terazosin, doxazosin). As monotherapy: patients with bladder overflow. anuria with or without progressive renal failure.
Use during pregnancy and lactation
Adequate and strictly controlled studies of the safety of doxazosin during pregnancy and lactation (breastfeeding) have not been conducted. Application is possible only in cases where the potential benefit to the mother outweighs the potential risk to the fetus or child.
Dosage and administration
The initial dose is 1 mg / day.After 1-2 weeks, depending on the clinical situation, the dose may be increased to 2 mg / day, and then after 1-2 weeks to 4 mg, 8 mg or 16 mg / day to achieve the optimal therapeutic effect. On average, the daily dose is 2-4 mg. Maximum dose: 16 mg / day.
Side effects
Since the cardiovascular system: orthostatic reactions (including fainting), tachycardia, arrhythmia, peripheral edema. On the part of the digestive system: nausea. From the side of the central nervous system: dizziness, headache, fatigue, irritability, asthenia, drowsiness. Other: rhinitis.
special instructions
Since the cardiovascular system: orthostatic reactions (including fainting), tachycardia, arrhythmia, peripheral edema. On the part of the digestive system: nausea. From the side of the central nervous system: dizziness, headache, fatigue, irritability, asthenia, drowsiness. Other: rhinitis.